Kexing Biopharm , Ltd. Overview
Get informed when a big investor buys or sells
+ Follow11.59%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Kexing Biopharm , Ltd. (688136.SS) currently reports a ROE of 11.59%. That is above the Healthcare sector average of -75.84%. Use the charts on this page to explore Kexing Biopharm , Ltd.'s ROE history and peer comparisons.
Kexing Biopharm , Ltd.'s ROE of 11.59% is higher than the Healthcare sector average of -75.84%. That is roughly 115.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Kexing Biopharm , Ltd.'s current 11.59% should be judged against Healthcare norms (sector average: -75.84%) and against 688136.SS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 11.59%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Kexing Biopharm , Ltd., and consider following 688136.SS for alerts when major investors trade the stock.
Kexing Biopharm , Ltd. is classified in the Healthcare sector. On ROE, it currently shows 11.59% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 688136.SS with unrelated industries.
